Chargement en cours...
Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye
The RAS and mTOR inhibitor S-trans-trans-farnesylthiosalicylic acid (FTS) is a promising anticancer agent with moderate potency, currently undergoing clinical trials as a chemotherapeutic agent. FTS has displayed its potential against a variety of cancers including endocrine resistant breast cancer....
Enregistré dans:
| Publié dans: | Mol Pharm |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5815365/ https://ncbi.nlm.nih.gov/pubmed/26992462 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.5b00906 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|